Four Pillars Oncology Program
The Noxopharm candidate Veyonda® is being investigated for activity against cancer and in inflammation and septic shock / COVID-19.
The Noxopharm 4-pillar strategy for Veyonda® in cancer aims to prove that adding Veyonda® to standard cancer treatments will enhance the effectiveness of:
Externally delivered radiation (DARRT)
Internally delivered radiation (LuPIN)
Checkpoint inhibitors (IONIC)
Veyonda® is currently not approved in Australia or any other country